KALA BIO (KALA)
Evaluates biotech AI infrastructure while preserving biologics assets for potential partners.
Something off on this page? Send us feedback.
Evaluates the licensed Researgency AI platform for biotech and pharmaceutical clients while preserving MSC-S biologics assets. Future activity on KPI-012 and KPI-014 depends on partners, strategic arrangements, or additional capital.
Evaluates two business lines: the licensed Researgency platform, an on-premises AI infrastructure offering for biotechnology and pharmaceutical clients, and retained MSC-S biologics assets. Its former ophthalmology operation developed therapies for rare and severe diseases of the front and back of the eye; KPI-012 and KPI-014 are now held for potential partners. Researgency is being evaluated as a platform-as-a-service initiative.
Researgency is licensed from Younet AI and intended for secure, purpose-built deployment within client environments. Future work on KPI-012, KPI-014, and related MSC-S intellectual property depends on licensing, collaborations, other strategic arrangements, or additional capital.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 30, 2025 | Mizuho Securities | Target | Target: — | Target: $1.50 |
| Sep 30, 2025 | Mizuho | Downgrade | ||
| Sep 29, 2025 | H.C. Wainwright | Downgrade | ||
| Sep 29, 2025 | Ladenburg Thalmann | Downgrade | ||
| Sep 29, 2025 | HC Wainwright & Co. | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.2M · Total debt $0 · Total assets $10.6M · Shareholders' equity $9.0M
- Revenue
- $0
- Operating income
- −$1.7M
- Net income
- −$1.6M
No dividends on record.
| Institutions | 0.18% | 34.0K shares | |
|---|---|---|---|
| 26 holders · as of Mar 31, 2026 | |||
| Insiders | 0.03% | 6.3K shares | |
| 10 holders · as of Oct 24, 2025 | |||
| Strategic holders | 0.22% | 41.8K shares | |
| 2 holders · as of Dec 3, 2025 | |||
| Other | 99.57% | 19.26M shares | |
| remainder | |||
19.34M company shares as of Sep 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Oxford Finance LLCStrategic10 percent owner | 0.17% | 32,400 | filed Dec 3, 2025 |
Baker Bros. Advisors LP1Strategicother: Former 10% owner | 0.05% | 9,430 | filed Oct 2, 2025 |
Renaissance Technologies LLCInstitution | 0.04% | 417,517 | as of Mar 31, 2026 |
Citadel Advisors LLCInstitution | 0.03% | 281,650 | as of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 0.03% | 261,061 | as of Mar 31, 2026 |
- Reported at 0.01% on May 15, 2026, under the 5% line, so no further filing is required.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 22, 2025 | Darius Kharabi | officer: CHIEF BUSINESS OFFICER | −20,806 | $0.8300 |
| Oct 22, 2025 | Romulus K. Brazzell | officer: SEE REMARKS | −46,748 | $0.8300 |
| Oct 22, 2025 | Todd Bazemore | director | −47,768 | $0.8300 |
| Oct 23, 2025 | Mary Reumuth | officer: CHIEF FINANCIAL OFFICER | −967 | $0.8200 |
| Oct 22, 2025 | Mary Reumuth | officer: CHIEF FINANCIAL OFFICER | −32,230 | $0.8300 |
- Nvidia
Drug-discovery AI platform with on-premises deployment options
- Schrödinger
Scientific software and AI-enabled drug-discovery platform
- Recursion Pharmaceuticals
AI-native platform for biotech and pharmaceutical discovery work
- Absci
Generative-AI platform for biologic drug creation
- Aldeyra Therapeutics
Clinical-stage developer of therapies for ocular diseases
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| KALA BIO | $0.5871 | −1.99% | $10.8M | — | — | — | — |
| Nvidia | $228.11 | −0.32% | $5.51T | 28.7 | 19.1 | 18.2 | +105.9% |
| Schrödinger | $30.73 | +0.10% | $2.26B | — | — | 8.7 | +7.5% |
| Recursion Pharmaceuticals | $4.02 | −0.67% | $2.08B | — | — | 38.0 | −61.8% |
| Absci | $10.84 | +1.44% | $1.66B | — | — | 1,065.7 | −49.4% |
| Aldeyra Therapeutics | $1.40 | +0.23% | $81.4M | — | — | — | — |
| Median | 28.7 | 19.1 | 28.1 | −20.9% |